| Detection of molecular signatures of homologous recombination deficiency in bladder cancer J Börcsök, M Diossy, Z Sztupinszki, A Prosz, V Tisza, S Spisak, O Rusz, ... Clinical Cancer Research 27 (13), 3734-3743, 2021 | 20 | 2021 |
| Apprentice electrician with electrical injury LO Goffeng, DR Stormoen, KB Veiersted Tidsskrift for Den norske legeforening, 2018 | 7* | 2018 |
| PD‐L1 expression and FGFR‐mutations among Danish patients diagnosed with metastatic urothelial carcinoma: A retrospective and descriptive study T Grantzau, BG Toft, LC Melchior, J Elversang, DR Stormoen, LH Omland, ... Apmis 130 (8), 498-506, 2022 | 5 | 2022 |
| Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires EB Steen-Olsen, DR Stormoen, CA Kristensen, IR Vogelius, ... European Archives of Oto-Rhino-Laryngology 279 (8), 4199-4206, 2022 | 5 | 2022 |
| ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer Y Zhou, J Börcsök, E Adib, SC Kamran, AJ Neil, K Stawiski, D Freeman, ... Science Advances 9 (47), eadg2263, 2023 | 4 | 2023 |
| Patient reported outcomes interfering with daily activities in prostate cancer patients receiving antineoplastic treatment DR Stormoen, C Baeksted, GA Taarnhøj, C Johansen, H Pappot Acta Oncologica 60 (4), 419-425, 2021 | 4 | 2021 |
| Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma A Prosz, H Duan, V Tisza, P Sahgal, S Topka, GT Klus, J Börcsök, ... Scientific Reports 13 (1), 20567, 2023 | 3 | 2023 |
| Status of metastatic bladder cancer treatment illustrated by a case LH Dohn, LH Omland, DR Stormoen, H Pappot Seminars in Oncology Nursing 37 (1), 151113, 2021 | 3 | 2021 |
| Real-world study of treatment with pembrolizumab among patients with advanced urothelial tract cancer in Denmark LH Omland, DR Stormoen, LH Dohn, A Carus, AB Als, NV Jensen, ... Bladder Cancer 7 (4), 413-425, 2021 | 2 | 2021 |
| Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial DR Stormoen, GA Taarnhøj, RB Friis, C Johansen, H Pappot Acta Oncologica 62 (7), 814-819, 2023 | 1 | 2023 |
| Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer Y Zhou, V D D'Andrea, SP Shanmugam, I Stelter, DR Stormoen, ... European urology, S0302-2838 (24) 02231-0, 2024 | | 2024 |
| An Exploratory Study of Early Immune Response Markers for Pembrolizumab in Urothelial Tract Cancer DR Stormoen, LH Omland, KW Mouw, Z Szallasi, SR Ostrowski, ... Uro 4 (1), 1-11, 2024 | | 2024 |
| Glomerular filtration rate measurement during platinum treatment for urothelial carcinoma: optimal methods for clinical practice DR Stormoen, UN Joensen, G Daugaard, P Oturai, E Hyllested, ... International Journal of Clinical Oncology, 1-9, 2024 | | 2024 |
| Patient-reported outcomes used actively in cancer patients undergoing antineoplastic treatment: A mini-review of the Danish landscape H Pappot, GA Taarnhøj, L Bentsen, RB Friis, C Bæksted, MG Christiansen, ... Computational and Structural Biotechnology Journal, 2023 | | 2023 |
| Bladder cancer. UN Joensen, PS Kingo, D Stormoen, A Carus, H Pappot Ugeskrift for laeger 185 (14), V02230082-V02230082, 2023 | | 2023 |
Helle PappotVerified email at regionh.dk
